S

SELLAS Life Sciences Group

D
SLS
USD
0.01
(0.8696%)
Market Closed
10,733.00
Volume
-0.59
EPS
-
Div Yield
-1.288889
P/E
74,625,697.68
Market Cap
Today
0.8696%
1 Week
-0.855%
1 Month
-7.937%
6 Months
-12.782%
12 Months
18.488%
Year To Date
10.476%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
I
IMRN
-0.09
(-4.5455%)
USD
B
BLCM
-0.0162
(-4.0878%)
USD
T
TNXP
0.0013
(0.9353%)
USD
A
ALT
0.43
(6.1166%)
USD
A
ARWR
0.055
(0.2579%)
USD
V
VCNX
0.019
(0.567%)
USD
O
ONTX
(%)
USD
P
PAVM
0.02
(1.9417%)
USD

Title:
SELLAS Life Sciences Group

Sector:
Healthcare
Industry:
Biotechnology
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Do you need help or have a question?
Contact Us